On December 15, 2024, Pharming Technologies B.V. ("Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a ...

Pharming has since started exploring new uses for the drug in acute kidney injury and COVID-19 pneumonia, whilst working on a gene therapy approach for HAE with Orchard Therapeutics.

Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) ...

Pharming Group (NASDAQ:PHAR) has nominated Fabrice Chouraqui as its new Executive Director and CEO, succeeding Sijmen de Vries.The appointment will be for a four-year term, subject to shareholder ...

Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...

A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. For more information about this conference ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following ...